Literature DB >> 26440051

HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism.

Armando Rojas1, Fernando Delgado-López2, Ramón Perez-Castro2, Ileana Gonzalez2, Jacqueline Romero2, Israel Rojas2, Paulina Araya2, Carolina Añazco2, Erik Morales3, Jorge Llanos4.   

Abstract

The monocyte-macrophage lineage shows a high degree of diversity and plasticity. Once they infiltrate tissues, they may acquire two main functional phenotypes, being known as the classically activated type 1 macrophages (M1) and the alternative activated type 2 macrophages (M2). The M1 phenotype can be induced by bacterial products and interferon-γ and exerts a cytotoxic effect on cancer cells. Conversely, the alternatively activated M2 phenotype is induced by Il-4/IL13 and promotes tumor cell growth and vascularization. Although receptor for advanced glycation end-products (RAGE) engagement in M1 macrophages has been reported by several groups to promote inflammation, nothing is known about the functionality of RAGE in M2 macrophages. In the current study, we demonstrate that RAGE is equally expressed in both macrophage phenotypes and that RAGE activation by high-mobility group protein box1 (HMGB1) promotes protumoral activities of M2 macrophages. MKN45 cells co-cultured with M2 macrophages treated with HMGB1 at different times displayed higher invasive abilities. Additionally, conditioned medium from HMGB1-treated M2 macrophages promotes angiogenesis in vitro. RAGE-targeting knockdown abrogates these activities. Overall, the present findings suggest that HMGB1 may contribute, by a RAGE-dependent mechanism, to the protumoral activities of the M2 phenotype.

Entities:  

Keywords:  HMGB1; Macrophage polarization; Receptor for advanced glycation end-products (RAGE); Tumor-associated macrophages

Mesh:

Substances:

Year:  2015        PMID: 26440051     DOI: 10.1007/s13277-015-3940-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  LPS-induced upregulation of SHIP is essential for endotoxin tolerance.

Authors:  Laura M Sly; Michael J Rauh; Janet Kalesnikoff; Christine H Song; Gerald Krystal
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 2.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

3.  Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Authors:  Hiroki Kuniyasu; Naohide Oue; Atsuko Wakikawa; Hideo Shigeishi; Norimasa Matsutani; Kazuya Kuraoka; Reiko Ito; Hiroshi Yokozaki; Wataru Yasui
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

Review 4.  Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.

Authors:  Armando Rojas; Hector Figueroa; Erik Morales
Journal:  Carcinogenesis       Date:  2009-12-22       Impact factor: 4.944

Review 5.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

Authors:  M P Wautier; O Chappey; S Corda; D M Stern; A M Schmidt; J L Wautier
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-05       Impact factor: 4.310

7.  Advanced glycosylation end products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells.

Authors:  Chih-Hsiung Wu; Chao-Ming Huang; Chien-Huang Lin; Yuan-Sun Ho; Chien-Ming Chen; Horng-Mo Lee
Journal:  Mol Cell Endocrinol       Date:  2002-08-30       Impact factor: 4.102

Review 8.  High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.

Authors:  Marco E Bianchi; Angelo A Manfredi
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

Review 9.  High mobility group box 1 protein, a cue for stem cell recruitment.

Authors:  Roberta Palumbo; Marco E Bianchi
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

Review 10.  Collaborating with the enemy: function of macrophages in the development of neoplastic disease.

Authors:  Andrzej Eljaszewicz; Małgorzata Wiese; Anna Helmin-Basa; Michal Jankowski; Lidia Gackowska; Izabela Kubiszewska; Wojciech Kaszewski; Jacek Michalkiewicz; Wojciech Zegarski
Journal:  Mediators Inflamm       Date:  2013-03-17       Impact factor: 4.711

View more
  25 in total

1.  M2 macrophages do not fly into a "RAGE".

Authors:  Armando Rojas; Carolina Añazco; Paulina Araya
Journal:  Inflamm Res       Date:  2016-10-03       Impact factor: 4.575

Review 2.  Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages.

Authors:  Armando Rojas; Paulina Araya; Jacqueline Romero; Fernando Delgado-López; Ileana Gonzalez; Carolina Añazco; Ramon Perez-Castro
Journal:  Cancer Microenviron       Date:  2018-08-08

3.  Tumor-associated macrophages in gastric cancer: more than bystanders in tumor microenvironment.

Authors:  Armando Rojas; Fernando Delgado-López; Ileana Gonzalez
Journal:  Gastric Cancer       Date:  2016-02-19       Impact factor: 7.370

Review 4.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 5.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

6.  C1q and HMGB1 reciprocally regulate human macrophage polarization.

Authors:  Myoungsun Son; Amit Porat; Mingzhu He; Jolien Suurmond; Frances Santiago-Schwarz; Ulf Andersson; Thomas R Coleman; Bruce T Volpe; Kevin J Tracey; Yousef Al-Abed; Betty Diamond
Journal:  Blood       Date:  2016-09-28       Impact factor: 22.113

7.  High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis.

Authors:  Qiang-Bo Zhang; Qing-An Jia; Hong Wang; Chun-Xiao Hu; Dong Sun; Run-De Jiang; Zong-Li Zhang
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

Review 8.  Chemotherapy and tumor microenvironment of pancreatic cancer.

Authors:  Qiaofei Liu; Quan Liao; Yupei Zhao
Journal:  Cancer Cell Int       Date:  2017-07-05       Impact factor: 5.722

Review 9.  High Mobility Group Box 1 in Human Cancer.

Authors:  Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

Review 10.  Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy.

Authors:  Barbara Joanna Bałan; Ewa Zygmanowska; Dorota Magdalena Radomska-Leśniewska
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.